Diffuse large B-cell lymphoma

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
Lunedì, Maggio 6, 2024
PSMA, FDA, Net, University, Part, DLBCL, EDT, City, CRS, Safety, PIN, University of Miami, Pancreatic cancer, Infrared spectroscopy correlation table, Research, Hematology, Insurance, PR, MD, Growth, ICU, Rituximab, Follicular lymphoma, ADC, Patient, Therapeutic index, Sarcoma, S&M, Diffuse large B-cell lymphoma, NHL, Cytokine release syndrome, Marketing, IIT, Advertising, Therapy, NSCLC, Spacecraft, AXL, Lung cancer, Pharmaceutical industry

Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.

Key Points: 
  • Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.
  • Net product revenues were $17.8 million for the first quarter 2024, compared to $19.0 million for the first quarter 2023.
  • R&D expenses were $25.7 million for the first quarter 2024, compared to $38.4 million for the first quarter 2023.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2024 financial results and provide a company update today at 8:30 a.m. Eastern Time.

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Retrieved on: 
Lunedì, Maggio 6, 2024
FDA, University, City, Safety, University of Miami, Doctor of Philosophy, ADC, Patient, Diffuse large B-cell lymphoma, NHL, Toxicity, Therapy, Pharmaceutical industry

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).

Key Points: 
  • LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).
  • As of the data cutoff date of March 30, 2024, 15 patients were evaluable.
  • Of these 15 patients evaluated, 13 achieved a complete response (CR) and one patient achieved a partial response (PR).
  • “Based on the initial data from University of Miami’s Phase 2 trial evaluating ZYNLONTA in relapsed/refractory MZL, we are encouraged by the potential opportunity in the 2L+ setting for patients with this rare disease.”

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Retrieved on: 
Giovedì, Aprile 4, 2024
B-cell lymphoma, Toxicity, Associate, Part, Patient, CRS, University, Doctor of Philosophy, Therapy, Diffuse large B-cell lymphoma, Infrared spectroscopy correlation table, Division, ADC, Hematology, Cytokine release syndrome, Lymphoma, Follicular lymphoma, Pharmaceutical industry

LAUSANNE, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with bispecific antibodies glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

Key Points: 
  • Additionally, after the first investigator assessment, evidence of anti-tumor activity was observed among the majority of patients, with mixed histologies including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and marginal zone lymphoma (MZL).
  • “The early data from Part 1 of our LOTIS-7 trial highlight the potential combinability of ZYNLONTA with bispecifics in lymphoma patients,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • The three dosing arms include ZYNLONTA plus polatuzumab vedotin, ZYNLONTA plus glofitamab, and ZYNLONTA plus mosunetuzumab T-cell-engaging bispecific monoclonal antibodies (BsAbs).
  • For more information about the LOTIS-7 trial, visit clinicaltrials.gov (NCT04970901).

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Mercoledì, Marzo 13, 2024
AXL, PIN, Neutropenia, Growth, Rituximab, Sarcoma, ALT, NSCLC, ASH, FY, Progression-free survival, Skin infection, Patient, Follicular lymphoma, S&M, Research, EDT, Aes, Periodic breathing, G&A, University, Lung cancer, Insurance, AACR, DLT, Pancreatic cancer, Hyperglycemia, Society, Therapy, Clinical trial, Diffuse large B-cell lymphoma, PFS, CD22, ADC, Data, Fatigue, MD Anderson Cancer Center, FDA, DLBCL, Marketing, PSMA, IDMC, Pharmaceutical industry

LAUSANNE, Switzerland, March 13, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided business updates.

Key Points: 
  • “In the fourth quarter we saw results of our strategy in action across a number of key areas.
  • A return to sequential quarter-over-quarter growth in the fourth quarter of 2023 followed the restructuring of the commercial model, with sales volume increasing in both community and academic settings.
  • R&D expenses were $30.3 million for the fourth quarter and $127.1 million for full year 2023, compared to $48.1 million and $186.5 million, respectively, for the fourth quarter and full year 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss fourth quarter and full year 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Retrieved on: 
Martedì, Dicembre 12, 2023
Patient, ALT, Diffuse large B-cell lymphoma, Aes, PET/CT, Progression-free survival, Fatigue, Neutropenia, GELF, Hyperglycemia, Doctor of Philosophy, Society, Follicular lymphoma, Therapy, Medicine, University, ASH, Rituximab, Skin infection, Periodic breathing, Toxicity, PFS, ADC, Pharmaceutical industry

LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab demonstrated a high response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL). The data from the single-institution study conducted at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine were reported during an oral presentation yesterday at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition by the study’s lead investigator, Juan Pablo Alderuccio, MD, associate professor of medicine and hematologist at Sylvester.

Key Points: 
  • LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab demonstrated a high response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL).
  • As of the data cutoff date of November 26, 2023, 33 patients were enrolled out of a targeted 39 patients.
  • R-CHOP was the most common first-line therapy (n=18; 54.5%) followed by bendamustine with rituximab (n=8; 24.2%) and single-agent rituximab (n=6; 18.2%).
  • The initial results are based on an analysis of 27 patients evaluable for efficacy and 32 patients evaluable for toxicity.

Industry Report Explores YESCARTA Drug Prospects and Market Forecast for DLBCL Treatment up to 2032 - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Dicembre 14, 2023
Health, Pharmaceutical, Research, Diffuse large B-cell lymphoma, PMBCL, Clinical trial, Patient, SWOT, EU4, Dietary supplement, Risk management, Medical imaging, Pharmaceutical industry, DLBCL

The "YESCARTA Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "YESCARTA Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • Crucial for industry stakeholders, the report offers future market assessments alongside comprehensive SWOT analysis, the analyst viewpoint on YESCARTA, and a competitive overview of market rivals.
  • YESCARTA (axicabtagene ciloleucel) represents a significant advancement in DLBCL treatment as a CD19-directed CAR-T cell immunotherapy.
  • How will evolving market trends and the entry of new therapies impact the forecasted market scenario for DLBCL treatment?

Foresight Diagnostics Presents Four Presentations and Two Posters Demonstrating Accuracy and Utility of PhasED-Seq™ ctDNA Platform for Early Response Assessment at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Martedì, Dicembre 12, 2023
Bristol Myers Squibb, Research, Catriona lonca, DNA, PET/CT, Therapy, Federal Medical Centres, ASH, Neoplasm, Foresight, Diffuse large B-cell lymphoma, ADC, Patient, MRD, Caregiver, University, Abstract, MD, BMS, Doctor of Philosophy, Society, Poster, Lymphoma, Drug development, Medical imaging, DLBCL

AURORA, Colo., Dec. 12, 2023 /PRNewswire/ -- Foresight Diagnostics, the leader in ultra-sensitive liquid biopsy MRD detection, announced multiple studies that consistently demonstrated higher clinical sensitivity and prognostic accuracy of Foresight Diagnostic's PhasED-Seq circulating tumor DNA (ctDNA) technology compared to that of standard-of-care imaging in patients with lymphoma. These findings mark a significant milestone for accelerating clinical development, giving the scientific community the data needed to confidently shift clinical response assessment away from solely relying on radiographic imaging to now incorporating ultra-sensitive ctDNA measurement as an earlier and more accurate indicator of response or relapse. The new data have been presented across four podium presentations and two posters during this year's American Society of Hematology (ASH) annual meeting.

Key Points: 
  • The new data have been presented across four podium presentations and two posters during this year's American Society of Hematology (ASH) annual meeting.
  • "We are getting to a point where there are few use cases in lymphoma where PET/CT is better than ctDNA/MRD.
  • In addition to these six abstracts co-authored with Foresight Diagnostics, additional abstracts will be reporting on ctDNA-MRD detection using Foresight's PhasED-Seq platform.
  • Foresight Diagnostics and its fellow co-authors and partners thank the patients, caregivers, investigators, and study personnel involved in the trials that provided the data for this research.

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

Retrieved on: 
Giovedì, Novembre 2, 2023
Poster, NYSE, 65th Berlin International Film Festival, Doctor of Philosophy, Research, AM, Society, ASH, San Diego Convention Center, Diffuse large B-cell lymphoma, ADC, Abstract, Rituximab, Therapy, Manchester Grand Hyatt Hotel, Patient, Pharmaceutical industry, MD

LAUSANNE, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023.

Key Points: 
  • LAUSANNE, Switzerland, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 9-12, 2023.
  • "We look forward to sharing insights from the growing body of research supporting the clinical utility of ZYNLONTA as a single agent and in combination with other treatments at the 65th ASH Annual Meeting,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • We look forward to additional details to be shared during the oral presentation.”
    Details of the oral presentation of the investigator-initiated study:
    Session: 623.
  • The abstracts are available through the ASH online meeting program.

ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

Retrieved on: 
Giovedì, Agosto 31, 2023
Lymphoma, Loncastuximab tesirine, Abstract, Polatuzumab vedotin, Society, Progression-free survival, Follicular lymphoma, Diffuse large B-cell lymphoma, DLBCL, Safety, SOHO, Doctor of Philosophy, B-cell lymphoma, Nanakaly Hospital for Hematology & Oncology, Mosunetuzumab, Dor, The Year's Best Science Fiction: Eleventh Annual Collection, ADC, Poster, Trial of the century, Therapy, NYSE, ORR, Medical device, Pharmaceutical industry, Fine chemical, Rituximab, MD, Patient

LAUSANNE, Switzerland, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that two ZYNLONTA® (loncastuximab tesirine-lpyl) abstracts have been accepted for presentation at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023), which will be held in Houston, Texas from September 6-9, 2023.

Key Points: 
  • For LOTIS-5, the Phase 3 study evaluating the combination of ZYNLONTA with rituximab, we are encouraged by the updated safety run-in results being presented at SOHO 2023.
  • It is the confirmatory trial for accelerated approval for 3L+ and would also support potential label expansion into 2L+ in combination with rituximab.
  • Dosing arms include ZYNLONTA (loncastuximab tesirine-lpyl) plus polatuzumab vedotin, as well as ZYNLONTA (loncastuximab tesirine-lpyl) plus glofitamab and mosunetuzumab, t-cell-engaging bispecific monoclonal antibodies (BsAbs).
  • Combining these agents with different mechanisms of action has the potential to have increased activity compared to either agent alone.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

Retrieved on: 
Giovedì, Luglio 27, 2023
Rituximab, Diffuse large B-cell lymphoma, DLBCL, Data monitoring committee, Patient, ADC, Pomerantz, News, NYSE, DMC, Pharmaceutical industry

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT).

Key Points: 
  • NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT).
  • The investigation concerns whether ADC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On July 11, 2023, ADC “announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial .
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.